(Q40534050)

21 September 2017

Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors (English)

1 reference

21 September 2017

1 reference

Anne S Tsao

1

1 reference

21 September 2017

Dong M Shin

2

1 reference

21 September 2017

J Lynn Palmer

3

1 reference

21 September 2017

Jin S Lee

4

1 reference

21 September 2017

Bonnie S Glisson

5

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

21 September 2017

1 reference

21 September 2017

100

1 reference

21 September 2017

10

1 reference

21 September 2017

2240-2245

1 reference

Eukaryotic DNA topoisomerases I.

21 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

New Natural Products Under Development at the National Cancer Institute

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Relationships between the structure of taxol analogs and their antimitotic activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Phase I trial of Taxotere: five-day schedule

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Vaccinia DNA topoisomerase I: evidence supporting a free rotation mechanism for DNA supercoil relaxation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Mechanism of the reaction catalyzed by the DNA untwisting enzyme: Attachment of the enzyme to 3′-terminus of the nicked DNA

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Future role of topotecan in the treatment of lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Topoisomerase I inhibitors: review and update

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Phase I study of docetaxel and topotecan in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20238

7 January 2021

Identifiers

DOI

10.1002/CNCR.20238

1 reference

21 September 2017

1 reference